Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | ROS1 | P08922 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24921221 | 0.80 | MAPT (0.41) | MAPTHSD17B10KDM4EGAANPSR1 | |
| SCHEMBL16583333 | 0.77 | APOBEC3A (0.56) | MAPTHSD17B10KDM4EGAANPSR1 | |
| SCHEMBL16583285 | 0.77 | HPGD (0.49) | MAPTHSD17B10KDM4ERAB9AHPGD | |
| SCHEMBL24921462 | 0.75 | L3MBTL1 (0.40) | MAPTHSD17B10KDM4EGAANPSR1 | |
| SCHEMBL16597167 | 0.73 | L3MBTL1 (0.44) | KDM4EL3MBTL1CHEK1EGFRNTRK1 | |
| SCHEMBL16583512 | 0.73 | L3MBTL1 (0.44) | MAPTHSD17B10KDM4EGAANPSR1 | |
| SCHEMBL16584035 | 0.73 | ACHE (0.40) | MAPTHSD17B10KDM4ERAB9AHPGD | |
| SCHEMBL24920871 | 0.73 | L3MBTL1 (0.41) | MAPTHSD17B10KDM4EGAANPSR1 | |
| SCHEMBL24920841 | 0.71 | MAPT (0.42) | MAPTHSD17B10KDM4EGAANPSR1 | |
| SCHEMBL16482009 | 0.71 | HSD17B10 (0.58) | MAPTHSD17B10KDM4EGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030556-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften (DE) | 2016-06-15 | — | — | EP | claimed |
| WO-2015039758-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-26 | — | — | WO | claimed |
| CN-105924433-B | Substituted aminopyrimidine compounds and use method and application thereof | 广东东阳光药业有限公司 | 2020-12-22 | — | — | CN | disclosed |
| EP-3046563-B1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AS PI3-KINASE INHIBITORS | CALITOR SCIENCES LLC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-9670194-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9518046-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160318913-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
| WO-2016149160-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-09-22 | — | — | WO | disclosed |
| EP-3046563-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015042077-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20150087663-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087663-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MYD88 | MAPT 4480/4885HSD17B10 3434/4885KDM4E 1020/4885 |
| US-20160318913-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MYD88 | MAPT 4477/4885HSD17B10 3336/4885KDM4E 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.